calquence
astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
nasoferm mentol 1 mg/ml nässpray, lösning
nordic drugs ab - xylometazolinhydroklorid - nässpray, lösning - 1 mg/ml - makrogolglycerolhydroxistearat hjälpämne; xylometazolinhydroklorid 1 mg aktiv substans; bensalkoniumklorid hjälpämne
ophthajod 50 mg/ml ögondroppar, lösning
vital pharma nordic aps - povidon, joderad - Ögondroppar, lösning - 50 mg/ml - povidon, joderad 50 mg aktiv substans; glycerol hjälpämne
nezebi 0,25 mg/ml nässpray, lösning
perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,25 mg/ml - oximetazolinhydroklorid 0,25 mg aktiv substans
nezeril dexpantenol 0,25 mg/ml nässpray, lösning
perrigo sverige ab - oximetazolinhydroklorid - nässpray, lösning - 0,25 mg/ml - oximetazolinhydroklorid 0,25 mg aktiv substans
epysqli
samsung bioepis nl b.v. - eculizumab - hemoglobinuri, paroxysmal - immunsuppressiva - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
perindopril arginine actavis 10 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; perindoprilarginin 10 mg aktiv substans
perindopril arginine actavis 2,5 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 2,5 mg aktiv substans
perindopril arginine actavis 5 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 5 mg aktiv substans